Arindel Maharaj
Ophthalmology · Miami, FLNPI 1003142365
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.6%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Oculus Surgical Inc. at 29.4% of the total. Reporting peaked in 2023 at $5,853 and has fallen 73.3% since, to $1,565 in 2025. Among ophthalmology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 153 payments — averaging $127.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Oculus Surgical Inc.$6K
- Dutch Ophthalmic, USA$3K
- Glaukos Corporation$2K
- Sight Sciences, Inc.$2K
- Alcon$2K
- Johnson & Johnson Surgical Vision, Inc.$2K
- plus $2K from 6 others
Across 5 payments — averaging $3249.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$16K
What the payments were for
- Consulting fees$6,80035%
- Speaking & faculty fees$3,25017%
- Food & beverage$9,49649%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Oculus Surgical Inc. | 5 | $5,750 |
| Dutch Ophthalmic, USA | 2 | $3,022 |
| Glaukos Corporation | 27 | $2,358 |
| Sight Sciences, Inc. | 31 | $2,266 |
| Alcon | 28 | $2,014 |
| Johnson & Johnson Surgical Vision, Inc. | 41 | $1,972 |
| Aerie Pharmaceuticals, Inc. | 1 | $1,300 |
| AbbVie(2 entities) | 13 | $651 |
| NEW World Medical,inc. | 2 | $146 |
| Regeneron Healthcare Solutions, Inc. | 1 | $28 |
| Baudax Bio Inc. | 1 | $23 |
| Rayner Intraocular Lenses Limited | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVA, combined machine$3,000
- TISSUEBLUE$3,000
- Gonio$2,500
- OMNI(R) SURGICAL SYSTEM (US)$1,598
- Rhopressa$1,300
- Rocklatan$1,300
- GONIO ready$1,000
- iStent inject W$643
- Clareon$534
- iDoseTR$459
- Tecnis IOL$453
- iStent$397
- XEN GLAUCOMA TREATMENT SYSTEM$385
- Tecnis Simplicity$340
- iStent Trabecular Micro-Bypass System Model iS3$321
- AcrySof IQ PanOptix UV IOL$292
- LenSx$276
- IACCESS$218
- ACTIVEFOCUS$147
- AcrySof$147
How this compares
$19,546 in reported general payments places this provider in the 90th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyzultaLatanoprostene Bunod | 282 | $136,131 |
| RhopressaNetarsudil Mesylate | 142 | $74,412 |
| CombiganBrimonidine Tartrate/Timolol | 129 | $68,015 |
| LumiganBimatoprost | 127 | $67,676 |
| Phospholine IodideEchothiophate Iodide | 14 | $35,134 |
| Methazolamide | 115 | $30,819 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 61 | $24,895 |
| Latanoprost | 2,077 | $23,497 |
| Brimonidine Tartrate | 962 | $23,373 |
| RestasisCyclosporine | 31 | $22,678 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 1,004 | $22,278 |
| Prednisolone Acetate | 476 | $21,843 |
| RocklatanNetarsudil Mesylat/Latanoprost | 30 | $19,565 |
| Pilocarpine Hcl | 279 | $18,339 |
| Timolol Maleate | 750 | $17,077 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCombigan, Lumigan, Restasis, Alphagan P | $651 | $170,637309 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $1,300 | $93,977172 claims |
| AlconSimbrinza, Azopt | $2,014 | $30,29574 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Miami
- William TrattlerMiami$579K
- Jennifer LohMiami$545K
- Jayanth SridharMiami$525K
- Kendall DonaldsonMiami$349K
- Jaclyn KovachMiami$333K
- Andrew SchimelMiami$320K
- Carlos BuznegoMiami$287K
- Felipe MedeirosMiami$266K
- Michael YimMiami$161K
- Arnulfo MansurMiami$134K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.